Margaret Kaczor
Stock Analyst at William Blair
(0.45)
# 3,062
Out of 4,413 analysts
20
Total ratings
38.46%
Success rate
-13.04%
Average return
Main Sectors:
13 Stocks
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
CVRX CVRx, Inc. | Downgrades: Market Perform | n/a | $9.12 | - | 2 | May 1, 2024 | |
CUTR Cutera | Upgrades: Market Perform | n/a | $2.26 | - | 3 | Mar 22, 2024 | |
INGN Inogen | Upgrades: Outperform | n/a | $6.91 | - | 4 | Feb 15, 2024 | |
SKIN The Beauty Health Company | Downgrades: Market Perform | n/a | $3.19 | - | 2 | Nov 14, 2023 | |
STAA STAAR Surgical Company | Downgrades: Market Perform | n/a | $45.81 | - | 1 | Jun 7, 2023 | |
VAPO Vapotherm | Downgrades: Market Perform | n/a | $1.20 | - | 1 | Aug 4, 2022 | |
NVRO Nevro | Downgrades: Market Perform | n/a | $10.48 | - | 1 | Aug 5, 2021 | |
AFIB Acutus Medical | Downgrades: Market Perform | n/a | $0.15 | - | 1 | Mar 19, 2021 | |
STIM Neuronetics | Upgrades: Outperform | n/a | $3.41 | - | 1 | Jan 22, 2021 | |
DVA DaVita | Assumes: Outperform | n/a | $138.11 | - | 1 | Jun 6, 2018 | |
MDT Medtronic | Assumes: Market Perform | n/a | $80.46 | - | 1 | Jun 6, 2018 | |
ABT Abbott Laboratories | Upgrades: Outperform | n/a | $106.31 | - | 1 | Jan 25, 2018 | |
DXCM DexCom | Initiates: Outperform | n/a | $125.04 | - | 1 | Apr 27, 2017 |
CVRx, Inc.
May 1, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $9.12
Upside: -
Cutera
Mar 22, 2024
Upgrades: Market Perform
Price Target: n/a
Current: $2.26
Upside: -
Inogen
Feb 15, 2024
Upgrades: Outperform
Price Target: n/a
Current: $6.91
Upside: -
The Beauty Health Company
Nov 14, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.19
Upside: -
STAAR Surgical Company
Jun 7, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $45.81
Upside: -
Vapotherm
Aug 4, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.20
Upside: -
Nevro
Aug 5, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $10.48
Upside: -
Acutus Medical
Mar 19, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.15
Upside: -
Neuronetics
Jan 22, 2021
Upgrades: Outperform
Price Target: n/a
Current: $3.41
Upside: -
DaVita
Jun 6, 2018
Assumes: Outperform
Price Target: n/a
Current: $138.11
Upside: -
Medtronic
Jun 6, 2018
Assumes: Market Perform
Price Target: n/a
Current: $80.46
Upside: -
Abbott Laboratories
Jan 25, 2018
Upgrades: Outperform
Price Target: n/a
Current: $106.31
Upside: -
DexCom
Apr 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $125.04
Upside: -